OBJECTIVES: The study used a model of 90 % portal branch ligation (PBL) in rats to study the effect of losartan on portal vein pressure (PVP) and liver regeneration in rats after PBL. METHODS: A total of 144 male Sprague-Dawley rats were arbitrarily designated into three treatment method groups: a sham operation group (Sham), a PBL treatment group (PBL), and a PBL plus losartan treatment group (PBL + L). Losartan (2 mg/day) was intragastrically gavaged 3 days before the PBL or sham operation to time points of study. RESULTS: Both the PBL and PBL + L groups showed an intense surge in PVP after PBL treatment, peaking at 12 h postsurgery, then lessening progressively afterwards. PVP was substantially greater in these two groups compared with the Sham group at 6-72 h postsurgery (p < 0.01). Compared with the PBL group, the PBL + L group showed a noticeable reduction in PVP 6-48 h postsurgery (p < 0.05); the PBL group showed considerably raised levels of plasma ALT and AST 6-72 h postsurgery (p < 0.01). Compared to the PBL group, the PBL + L group showed drastically reduced plasma ALT and AST levels 12-72 h postsurgery (p < 0.05). CONCLUSIONS: Losartan supports liver regeneration in 90 % of rats that underwent PBL. The mechanism may be related to losartan's ability to regulate PVP and increase serum hepatocyte growth factor levels.
OBJECTIVES: The study used a model of 90 % portal branch ligation (PBL) in rats to study the effect of losartan on portal vein pressure (PVP) and liver regeneration in rats after PBL. METHODS: A total of 144 male Sprague-Dawley rats were arbitrarily designated into three treatment method groups: a sham operation group (Sham), a PBL treatment group (PBL), and a PBL plus losartan treatment group (PBL + L). Losartan (2 mg/day) was intragastrically gavaged 3 days before the PBL or sham operation to time points of study. RESULTS: Both the PBL and PBL + L groups showed an intense surge in PVP after PBL treatment, peaking at 12 h postsurgery, then lessening progressively afterwards. PVP was substantially greater in these two groups compared with the Sham group at 6-72 h postsurgery (p < 0.01). Compared with the PBL group, the PBL + L group showed a noticeable reduction in PVP 6-48 h postsurgery (p < 0.05); the PBL group showed considerably raised levels of plasma ALT and AST 6-72 h postsurgery (p < 0.01). Compared to the PBL group, the PBL + L group showed drastically reduced plasma ALT and AST levels 12-72 h postsurgery (p < 0.05). CONCLUSIONS:Losartan supports liver regeneration in 90 % of rats that underwent PBL. The mechanism may be related to losartan's ability to regulate PVP and increase serum hepatocyte growth factor levels.
Authors: Anthony J Demetris; Dympna M Kelly; Bijan Eghtesad; Paulo Fontes; J Wallis Marsh; Kusum Tom; Heinke P Tan; Thomas Shaw-Stiffel; Linda Boig; Paula Novelli; Raymond Planinsic; John J Fung; Amadeo Marcos Journal: Am J Surg Pathol Date: 2006-08 Impact factor: 6.394
Authors: J S Campbell; L Prichard; F Schaper; J Schmitz; A Stephenson-Famy; M E Rosenfeld; G M Argast; P C Heinrich; N Fausto Journal: J Clin Invest Date: 2001-05 Impact factor: 14.808
Authors: Y Taniyama; R Morishita; H Nakagami; A Moriguchi; H Sakonjo; K Matsumoto; T Nakamura; J Higaki; T Ogihara Journal: Circulation Date: 2000-07-11 Impact factor: 29.690
Authors: Donatella R Di Stefano; Thierry de Baere; Alban Denys; Antoine Hakime; Gilles Gorin; Michel Gillet; Jean Saric; Hervé Trillaud; Philippe Petit; Jean-Michel Bartoli; Dominique Elias; Jean-Robert Delpero Journal: Radiology Date: 2004-12-10 Impact factor: 11.105
Authors: Chang-Goo Huh; Valentina M Factor; Aránzazu Sánchez; Koichi Uchida; Elizabeth A Conner; Snorri S Thorgeirsson Journal: Proc Natl Acad Sci U S A Date: 2004-03-30 Impact factor: 11.205